New drug approvals in acute myeloid leukemia: what’s the best end point?

por Estey, E, Othus, M, Lee, S J, Appelbaum, F R, Gale, R P
Publicado 2015

MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma

por Xiong, J, Wang, L, Fei, X-C, Jiang, X-F, Zheng, Z, Zhao, Y, Wang, C-F, Li, B, Chen, S-J, Janin, A, Gale, R P, Zhao, W-L
Publicado 2017

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

por Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P
Publicado 2017

Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

por Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, McMullin, M F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P
Publicado 2017